Nov 29 |
Kazia stock jumps after proposed license deal for paxalisib outside oncology
|
Nov 29 |
KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY
|
Nov 18 |
Kazia Therapeutics Limited's (NASDAQ:KZIA) large institutional owners must be happy as stock continues to impress, up 28% over the past week
|
Nov 15 |
KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING
|
Nov 1 |
Kazia issues update on paxalisib study in CNS lymphoma patients
|
Nov 1 |
KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA
|